-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36

Benzinga·09/03/2026 20:58:41
Listen to the news
JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.